Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 5/20 | 0.52 |
| ▸ | CTSL | P07711 | 5/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962929 | 0.88 | PKM (0.70) | CTSVCTSLPKMCYP19A1MEN1 | |
| SCHEMBL5466233 | 0.82 | PKM (0.57) | CTSVCTSLPKMMEN1KMT2A | |
| SCHEMBL2986814 | 0.81 | HPD (0.57) | CTSVCTSLFOLH1MEN1KMT2A | |
| SCHEMBL7822540 | 0.81 | CTSV (0.53) | CTSVCTSLPKMMEN1KMT2A | |
| SCHEMBL9348425 | 0.81 | SMN1; SMN2 (0.57) | CTSVCTSLPKMFOLH1CYP19A1 | |
| SCHEMBL4301163 | 0.80 | FOLH1 (0.55) | CTSVCTSLFOLH1MEN1KMT2A | |
| SCHEMBL12253970 | 0.80 | PTPN1 (0.47) | CTSVCTSLPKMCYP19A1MEN1 | |
| SCHEMBL3842143 | 0.80 | PKM (0.55) | CTSVCTSLPKMFOLH1CYP19A1 | |
| SCHEMBL8316504 | 0.80 | CTSV (0.61) | CTSVCTSLFOLH1CYP19A1MEN1 | |
| SCHEMBL6767012 | 0.79 | FOLH1 (0.54) | CTSVCTSLFOLH1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040247698-A1 | Erectile Dysfunction Treatment | VALENZUELA CORTES CARMEN MARIA (CL) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040247698-A1 | Erectile Dysfunction Treatment | PDE3A, PDE3B, PDE12 | CTSV 4265/4885CTSL 4051/4885PKM 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.